European Study to Describe Hospital Stay in Patients Admitted for Acute Bipolar Manic Episodes Treated With Immediate Release Quetiapine or Extended Release Quetiapine

AstraZeneca1 site in 1 country1,280 target enrollmentNovember 2010

ConditionsAcute Bipolar Manic Episode

Overview

Phase: Not Applicable
Intervention: Not specified
Conditions: Acute Bipolar Manic Episode
Sponsor: AstraZeneca
Enrollment: 1280
Locations: 1
Primary Endpoint: Length of hospital stay
Status: Completed
Last Updated: 15 years ago

Overview Investigators Eligibility Criteria Outcomes Sites Similar Trials

Overview

Brief Summary

This study is being carried out to find out how patients suffering from the acute manic phase of bipolar disease are currently managed with Quetiapine Immediate Release (IR) or Quetiapine Extended Release (XR) in the hospital setting in real life practice, including length of stay.

Registry

clinicaltrials.gov

Start Date

November 2010

End Date

March 2011

Last Updated

15 years ago

Study Type

Observational

Sex

All

Investigators

Sponsor

AstraZeneca

Eligibility Criteria

Inclusion Criteria

•Patients diagnosed with Bipolar Disorder (ICD-10).
•Admitted for acute bipolar manic episode from 1st October 2009 to 1st October 2010
•Patients treated with quetiapine IR or quetiapine XR during the hospitalization period.

Exclusion Criteria

•Patients in which BD is not the main reason for hospitalization
•Patients admitted for acute bipolar mania episodes but finally diagnosed with mixed or bipolar disorder not otherwise specified (NOS) episodes
•Patients receiving both quetiapine IR and XR during the same hospitalization period.